The article "Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies" by Anna Maria Mazzola et al. provides an overview of the current knowledge and future prospects of the gluten-free diet (GFD) for celiac disease (CD) and other gluten-related disorders. The GFD is the primary treatment for CD, but strict adherence can be challenging due to social isolation, contamination risks, high costs, and poor quality of gluten-free products. The article discusses the development of gluten-free wheat flours to improve the sensory and nutritional qualities of these products. However, adherence to the GFD can impact patients' psychosocial quality of life, leading to psychological distress and anxiety. Various methods, including clinical assessments, questionnaires, serology, endoscopy, and detection of Gluten Immunogenic Peptides (GIPs), are used to monitor adherence, but none are entirely satisfactory. The article also highlights the challenges of gluten contamination in labeled and unlabelled foods, nutritional imbalances, and the need for vigilant label reading. New ingredients and flours, such as pseudocereals and legumes, are being explored to improve the quality and nutritional profile of gluten-free products. Additionally, emerging therapies beyond the GFD, including pharmacological treatments targeting gluten neutralization, tight junction regulation, and immunomodulation, are discussed. The aim is to enhance treatment efficacy and improve the quality of life for patients with CD and other gluten-related disorders.The article "Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies" by Anna Maria Mazzola et al. provides an overview of the current knowledge and future prospects of the gluten-free diet (GFD) for celiac disease (CD) and other gluten-related disorders. The GFD is the primary treatment for CD, but strict adherence can be challenging due to social isolation, contamination risks, high costs, and poor quality of gluten-free products. The article discusses the development of gluten-free wheat flours to improve the sensory and nutritional qualities of these products. However, adherence to the GFD can impact patients' psychosocial quality of life, leading to psychological distress and anxiety. Various methods, including clinical assessments, questionnaires, serology, endoscopy, and detection of Gluten Immunogenic Peptides (GIPs), are used to monitor adherence, but none are entirely satisfactory. The article also highlights the challenges of gluten contamination in labeled and unlabelled foods, nutritional imbalances, and the need for vigilant label reading. New ingredients and flours, such as pseudocereals and legumes, are being explored to improve the quality and nutritional profile of gluten-free products. Additionally, emerging therapies beyond the GFD, including pharmacological treatments targeting gluten neutralization, tight junction regulation, and immunomodulation, are discussed. The aim is to enhance treatment efficacy and improve the quality of life for patients with CD and other gluten-related disorders.